{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:17:50Z","timestamp":1788808670773,"version":"build-2803163510"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Canc Conf J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This case highlights the potential for early emergence of neuroendocrine differentiation in patients with metastatic castration-sensitive prostate cancer undergoing triplet therapy with androgen deprivation therapy, darolutamide, and docetaxel, even with marked prostate-specific antigen (PSA) suppression. In this patient, although some lesions initially responded to treatment, new metastases and radiological progression were observed early after triplet therapy was initiated. These atypical progression patterns raised the suspicion of neuroendocrine prostate cancer (NEPC), confirmed by percutaneous biopsy of an enlarged right external iliac lymph node. This enabled the timely modification of the treatment strategy. Furthermore, retrospective immunohistochemical reevaluation of the diagnostic prostate biopsy specimen obtained at the referring hospital using only four cores revealed focal neuroendocrine differentiation within the poorly differentiated Gleason pattern 5 areas, suggesting that de novo NEPC features may have been present at the time of diagnosis. As triplet therapy has become more widespread, the incidence of NEPC may increase. Clinicians should maintain a high level of vigilance for discordant PSA progression and consider early biopsy of metastatic lesions to ensure accurate diagnosis and appropriate therapeutic decision-making.<\/jats:p>","DOI":"10.1007\/s13691-025-00812-8","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:22:43Z","timestamp":1760016163000},"page":"41-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Early emergence of neuroendocrine prostate cancer during triplet therapy for high-volume metastatic castration-sensitive prostate cancer"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3723-8058","authenticated-orcid":false,"given":"Yuichiro","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Kurata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyohei","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Mitsunari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kojiro","family":"Ohba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoichi","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"812_CR1","unstructured":"National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology: prostate cancer, version 1.2026"},{"issue":"11","key":"812_CR2","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/jjco\/hyae098","volume":"54","author":"F Urabe","year":"2024","unstructured":"Urabe F, Imai Y, Goto Y et al (2024) Real-world evidence of triplet therapy efficacy in patients with metastatic castration-sensitive prostate cancer: a Japanese multicenter study. Jpn J Clin Oncol 54(11):1208\u20131213. https:\/\/doi.org\/10.1093\/jjco\/hyae098","journal-title":"Jpn J Clin Oncol"},{"issue":"24","key":"812_CR3","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","volume":"36","author":"R Aggarwal","year":"2018","unstructured":"Aggarwal R, Huang J, Alumkal JJ et al (2018) Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol 36(24):2492\u20132503. https:\/\/doi.org\/10.1200\/JCO.2017.77.6880","journal-title":"J Clin Oncol"},{"issue":"4","key":"812_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/iju.13526","volume":"25","author":"S Akamatsu","year":"2018","unstructured":"Akamatsu S, Inoue T, Ogawa O, Gleave ME (2018) Clinical and molecular features of treatment-related neuroendocrine prostate cancer. Int J Urol 25(4):345\u2013351. https:\/\/doi.org\/10.1111\/iju.13526","journal-title":"Int J Urol"},{"issue":"4","key":"812_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1111\/j.1464-410X.2006.06041.x","volume":"97","author":"TR Asmis","year":"2006","unstructured":"Asmis TR, Reaume MN, Dahrouge S, Malone S (2006) Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at the Ottawa hospital regional cancer center. BJU Int 97(4):711\u2013715. https:\/\/doi.org\/10.1111\/j.1464-410X.2006.06041.x","journal-title":"BJU Int"},{"issue":"4","key":"812_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrurol.2014.21","volume":"11","author":"R Nadal","year":"2014","unstructured":"Nadal R, Schweizer M, Kryvenko ON, Epstein JI, Eisenberger MA (2014) Small cell carcinoma of the prostate. Nat Rev Urol 11(4):213\u2013219. https:\/\/doi.org\/10.1038\/nrurol.2014.21","journal-title":"Nat Rev Urol"},{"issue":"5","key":"812_CR7","doi-asserted-by":"publisher","first-page":"e793","DOI":"10.1016\/j.clgc.2017.04.006","volume":"15","author":"E Zaffuto","year":"2017","unstructured":"Zaffuto E, Pompe R, Zanaty M et al (2017) Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis. Clin Genitourin Cancer 15(5):e793\u2013e800. https:\/\/doi.org\/10.1016\/j.clgc.2017.04.006","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"812_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.clgc.2011.12.004","volume":"10","author":"DV Matei","year":"2012","unstructured":"Matei DV, Renne G, Pimentel M et al (2012) Neuroendocrine differentiation in castration-resistant prostate cancer: a systematic diagnostic attempt. Clin Genitourin Cancer 10(3):164\u2013173. https:\/\/doi.org\/10.1016\/j.clgc.2011.12.004","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"812_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H (2021) Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep 23(2):15. https:\/\/doi.org\/10.1007\/s11912-020-01003-9","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"812_CR10","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.euo.2024.12.014","volume":"8","author":"D S\u00e9guier","year":"2025","unstructured":"S\u00e9guier D, Parent P, Duterque-Coquillaud M et al (2025) Emergence of neuroendocrine tumors in patients treated with androgen receptor pathway inhibitors for metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol 8(2):581\u2013590. https:\/\/doi.org\/10.1016\/j.euo.2024.12.014","journal-title":"Eur Urol Oncol"},{"key":"812_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","volume":"121","author":"V Conteduca","year":"2019","unstructured":"Conteduca V, Oromendia C, Eng KW et al (2019) Clinical features of neuroendocrine prostate cancer. Eur J Cancer 121:7\u201318. https:\/\/doi.org\/10.1016\/j.ejca.2019.08.011","journal-title":"Eur J Cancer"},{"issue":"5","key":"812_CR12","doi-asserted-by":"publisher","first-page":"719","DOI":"10.6004\/jnccn.2014.0073","volume":"12","author":"R Aggarwal","year":"2014","unstructured":"Aggarwal R, Zhang T, Small EJ, Armstrong AJ (2014) Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes. J Natl Compr Canc Netw 12(5):719\u2013726. https:\/\/doi.org\/10.6004\/jnccn.2014.0073","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"812_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nm.4045","volume":"22","author":"H Beltran","year":"2016","unstructured":"Beltran H, Prandi D, Mosquera JM et al (2016) Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. Nat Med 22(3):298\u2013305. https:\/\/doi.org\/10.1038\/nm.4045","journal-title":"Nat Med"},{"issue":"6320","key":"812_CR14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1126\/science.aah4199","volume":"355","author":"SY Ku","year":"2017","unstructured":"Ku SY, Rosario S, Wang Y et al (2017) Rb1 and Trp53 cooperation to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance. Science 355(6320):78\u201383. https:\/\/doi.org\/10.1126\/science.aah4199","journal-title":"Science"},{"issue":"2","key":"812_CR15","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1002\/path.5137","volume":"246","author":"EC Chedgy","year":"2018","unstructured":"Chedgy EC, Vandekerkhove G, Herberts C et al (2018) Biallelic tumour suppressor loss and DNA repair defects in de novo small-cell-prostate carcinoma. J Pathol 246(2):244\u2013253. https:\/\/doi.org\/10.1002\/path.5137","journal-title":"J Pathol"},{"issue":"10","key":"812_CR16","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N et al (2023) Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 21(10):1067\u20131096. https:\/\/doi.org\/10.6004\/jnccn.2023.0050","journal-title":"J Natl Compr Canc Netw"}],"container-title":["International Cancer Conference Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-025-00812-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13691-025-00812-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-025-00812-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T10:33:22Z","timestamp":1769250802000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13691-025-00812-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["812"],"URL":"https:\/\/doi.org\/10.1007\/s13691-025-00812-8","relation":{},"ISSN":["2192-3183"],"issn-type":[{"value":"2192-3183","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Written informed consent for publication of this case report and any accompanying images was obtained from the patient\u2019s legal representative.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}